首页> 外文学位 >Polymeric Micelles for Combination Drug Delivery in Cancer Therapy.
【24h】

Polymeric Micelles for Combination Drug Delivery in Cancer Therapy.

机译:用于癌症治疗中组合药物递送的聚合物胶束。

获取原文
获取原文并翻译 | 示例

摘要

Single small molecule drug therapy is often hindered by drug resistance that develops in cancer cells. Delivery of small interfering RNA (siRNA) to cells via drug delivery systems (DDS) is one effective approach to silence these resistance genes, often successfully re-sensitizing cancer cells to anticancer drugs. Polymeric nanoparticles have been widely explored to protect and deliver siRNA therapeutically. Combination delivery of siRNA and chemotherapeutic drugs is effective against different molecular targets and can increase the sensitization of cancer cells to chemotherapy, thereby overcoming drug resistance.;A three layer (trilayer) polymeric micelle system based on the self-association of the triblock copolymer poly(ethylene glycol)-b-poly{N-[N-(2-aminoethyl)-2-aminoethyl] aspartamide}-b-poly(epsilon-caprolactone) (PEG-b-PAsp(DET)-b-PCL) was synthesized to deliver rapamycin (RAP) and siRNA targeting Y-box binding protein-1 (siYB-1). The trilayer micelle is composed of (a) a hydrophilic poly(ethylene glycol) (PEG) block constituting the outer layer to improve pharmacokinetics, (b) an intermediate compartment composed of the cationic poly{2-[(2-aminoethyl)amino] ethyl aspartamide} (PAsp(DET)) segment for interacting with siYB-1, and (c) an inner hydrophobic poly(epsilon-caprolactone) (PCL) compartment for encapsulation of RAP. PEG and PCL are both approved by the FDA, and PAsp(DET) is a non-toxic pH responsive cationic poly(amino acid)-based polymer. We showed that PCL can encapsulate RAP with high loading efficiencies, and PAsp(DET) interacts with siRNA for efficient transfection/knockdown with negligible cytotoxicity. Enhanced therapeutic efficacy of RAP/siYB-1 micelles was demonstrated in cell cultures and in a PC3 xenograft nude mouse model of human prostate cancer.;We also developed a micelle formulation based on the self-association of PEG-b-PCL to deliver another anticancer drug, citral. Citral is found in the essential oils of many plants. Although it is composed of a random mixture of the two terpenoid isomers geranial (trans-citral) and neral (cis-citral), few studies have directly compared the in vivo antitumor properties of these isomers.;The antitumor properties of drug formulations were evaluated on the 4T1 xenograft mouse model. Geranial was found to be the more potent isomer of citral and western blot of tumor tissues confirmed that autophagy and not apoptosis was the major mechanism of tumor growth inhibition in p53-null 4T1 cells.
机译:单个小分子药物疗法通常会受到癌细胞中产生的耐药性的阻碍。通过药物递送系统(DDS)将小干扰RNA(siRNA)递送至细胞是使这些抗性基因沉默的一种有效方法,通常可以成功地使癌细胞对抗癌药物重新敏感。聚合物纳米颗粒已被广泛研究以治疗性地保护和递送siRNA。 siRNA和化学治疗药物的联合递送可有效地针对不同的分子靶标,并可以增强癌细胞对化学疗法的敏感性,从而克服耐药性。;基于三嵌段共聚物聚体自缔合的三层(三层)聚合物胶束系统(乙二醇)-b-聚{N- [N-(2-氨基乙基)-2-氨基乙基]天冬酰胺} -b-聚(ε-己内酯)(PEG-b-PAsp(DET)-b-PCL)为合成以递送雷帕霉素(RAP)和靶向Y盒结合蛋白1(siYB-1)的siRNA。三层胶束由(a)构成外层以改善药代动力学的亲水性聚(乙二醇)(PEG)嵌段组成,(b)由阳离子聚{2-[(2-氨基乙基)氨基]组成的中间部分(pasp(DET))段与siYB-1相互作用,(c)内部疏水性聚ε-己内酯(PCL)隔室,用于RAP封装。 PEG和PCL均已获得FDA批准,PAsp(DET)是一种无毒的pH响应型阳离子聚氨基酸聚合物。我们表明,PCL可以封装具有高加载效率的RAP,并且PAsp(DET)与siRNA相互作用,可进行有效的转染/抑制,且细胞毒性可忽略不计。在人类前列腺癌的细胞培养和PC3异种移植裸鼠模型中证明了RAP / siYB-1胶束具有更高的治疗功效。;我们还基于PEG-b-PCL的自缔合开发了一种胶束制剂,以提供另一个抗癌药,柠檬醛。柠檬醛存在于许多植物的精油中。尽管它是由两个萜类异构体geranial(反式-柠檬醛)和neral(顺式-柠檬醛)的随机混合物组成,但很少有研究直接比较这些异构体的体内抗肿瘤特性。;评估了药物制剂的抗肿瘤特性在4T1异种移植小鼠模型上。人们发现,香叶醛是柠檬酸的更强效异构体,肿瘤组织的蛋白质印迹证实,自噬而非凋亡是p53缺失4T1细胞抑制肿瘤生长的主要机制。

著录项

  • 作者

    Zeng, San.;

  • 作者单位

    The University of Wisconsin - Madison.;

  • 授予单位 The University of Wisconsin - Madison.;
  • 学科 Pharmaceutical sciences.;Biomedical engineering.;Oncology.
  • 学位 Ph.D.
  • 年度 2015
  • 页码 104 p.
  • 总页数 104
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号